http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020201000-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9dd824ddad33648c66984647bd72e120 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate | 2020-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25673ea06003d5941ccf16ad265ba4b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c20b9fb3b3ebbbfef635980e34af822 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8aff39dbe554becf2852b51aac69c8b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_662059efcbe7029aada0368effec463a |
| publicationDate | 2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2020201000-A1 |
| titleOfInvention | High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same |
| abstract | HIGH-PURITY INHALABLE PARTICLES OF INSULIN AND INSULIN ANALOGUES, AND HIGH-EFFICIENCY METHODS OF MANUFACTURING THE SAME A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) 10 the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 pm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable 15 insulin material. The yield rate for the high-efficiency method is 75 to 85% or more. -44- |
| priorityDate | 2016-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.